News & Updates

High-risk opioid use prevalent in patients with haematologic malignancy

06 Dec 2024

Many adult patients with haematologic malignancies (HM) have high-risk opioid use, which can increase their risk of opioid-related harms, reveals a study.

High-risk opioid use prevalent in patients with haematologic malignancy

06 Dec 2024

Colonoscopy intervals may be extended beyond 10 years for people at low CRC risk

06 Dec 2024

Negative colonoscopy screening findings appear to be associated with lower colorectal cancer (CRC) incidence and mortality for 20 years, and as such, rescreening intervals may be extended beyond the currently recommended 10 years for people with a low-risk profile, according to a study.

Colonoscopy intervals may be extended beyond 10 years for people at low CRC risk

06 Dec 2024

Depression care costs forecasted to surpass HKD 2.5 billion annually by 2032

06 Dec 2024 by

The costs of all-cause and psychiatric care for depression are projected to reach HKD 2.5 billion annually by 2032, with HKD 473.5 million specifically attributable to psychiatric care, according to a 10-year predictive modelling study based on real-world data.

Depression care costs forecasted to surpass HKD 2.5 billion annually by 2032

06 Dec 2024

Atrial fibrillation and COVID-19: An expert’s insights

06 Dec 2024

COVID-19 infection is not a simple respiratory illness. The damage set off by the virus is systemic, affecting not only the lungs but multiple organs, including the heart. At a Pfizer-sponsored symposium held at AFCC 2024 in Singapore, Dr William Kristanto, cardiologist at Cardiac Care Partners, Mount Elizabeth Medical Centre, Singapore, talked about atrial fibrillation and COVID-19, including the use of oral antiviral nirmatrelvir/ritonavir in adults at high risk for severe disease.

Atrial fibrillation and COVID-19: An expert’s insights

06 Dec 2024

Original New Drug Application Approvals by US FDA (16-30 November 2024)

06 Dec 2024

New drug applications approved by US FDA as of 16-30 November 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 November 2024)

06 Dec 2024

Age at T2DM diagnosis a major factor for subsequent adverse outcomes

05 Dec 2024 by

For individuals with type 2 diabetes mellitus (T2DM), the earlier the age at diagnosis, the higher the likelihood of subsequent coronary heart disease (CHD), stroke, cancer, and all-cause death, as shown in a study.

Age at T2DM diagnosis a major factor for subsequent adverse outcomes

05 Dec 2024

Treatment inequality persists in individuals with AUD

05 Dec 2024

Racial/ethnic and socioeconomic disparities exist in the treatment of individuals with alcohol use disorder (AUD), a study has found.

Treatment inequality persists in individuals with AUD

05 Dec 2024

TRT shows promise as adjunct treatment in rehabilitating ICU patients

05 Dec 2024 by

Testosterone replacement therapy (TRT) has the potential to be an effective adjunct treatment in the rehabilitation of critically ill patients with intensive care unit (ICU)-associated weakness (AW) and hospital-associated deconditioning (HAD), according to a Singapore study.

TRT shows promise as adjunct treatment in rehabilitating ICU patients

05 Dec 2024

Histotripsy 2.0 available for liver and breast cancer clinical trials in HK

05 Dec 2024 by

Asia’s first histotripsy 2.0 system, introduced at the Chinese University Hong Kong (CUHK) recently, will be used in clinical trials to treat liver cancer patients from early 2025. The novel focal therapy will also be evaluated in patients with early-stage breast cancer.

Histotripsy 2.0 available for liver and breast cancer clinical trials in HK

05 Dec 2024

What drives the beneficial effects of tirzepatide on glycaemic control?

05 Dec 2024

Use of tirzepatide results in better glycaemic control when compared with semaglutide, as shown by improved fasting glucose and glucose excursion control brought about by improvements in insulin secretion rate (ISR), insulin sensitivity, and glucagon suppression, according to a study.

What drives the beneficial effects of tirzepatide on glycaemic control?

05 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

High-risk opioid use prevalent in patients with haematologic malignancy

High-risk opioid use prevalent in patients with haematologic malignancy

Colonoscopy intervals may be extended beyond 10 years for people at low CRC risk

Colonoscopy intervals may be extended beyond 10 years for people at low CRC risk

Depression care costs forecasted to surpass HKD 2.5 billion annually by 2032

Depression care costs forecasted to surpass HKD 2.5 billion annually by 2032

Atrial fibrillation and COVID-19: An expert’s insights

Atrial fibrillation and COVID-19: An expert’s insights

Original New Drug Application Approvals by US FDA (16-30 November 2024)

Original New Drug Application Approvals by US FDA (16-30 November 2024)

Age at T2DM diagnosis a major factor for subsequent adverse outcomes

Age at T2DM diagnosis a major factor for subsequent adverse outcomes

Treatment inequality persists in individuals with AUD

Treatment inequality persists in individuals with AUD

TRT shows promise as adjunct treatment in rehabilitating ICU patients

TRT shows promise as adjunct treatment in rehabilitating ICU patients

Histotripsy 2.0 available for liver and breast cancer clinical trials in HK

Histotripsy 2.0 available for liver and breast cancer clinical trials in HK

What drives the beneficial effects of tirzepatide on glycaemic control?

What drives the beneficial effects of tirzepatide on glycaemic control?